FINNENCE▪
00:00:00 UTCSYS ONLINE
FINNENCE ▪ THE WIRE FILE

THE WIRE · № 79778

Company■ Mixed

Phase 3 results posted: A Study of Adeno-Associated Virus Serotype 8-Mediated Gene Transfer of Glucose-6-Phosphatase in Patients With Glycogen Storage Disease Type Ia (GSDIa) — Ultragenyx Pharmaceutical Inc

KINDCompany
DIRECTION■ Mixed
SOURCES1
ENTITIES2
STORY SIZESTANDALONE
FIRST SEEN
LAST UPDATE
STATEactive

01 THE MACHINE READ

WHY IT MATTERS.

Phase 3 results for a gene therapy could shift sentiment on Ultragenyx and rare-disease peers.

Gene therapy data point for rare disease
CATALYST TO WATCH

Company interpretation and regulatory next steps

MAIN RISK

Results direction not stated in text

FULL DISPATCH

Sponsor: Ultragenyx Pharmaceutical Inc; Status: Completed; Conditions: Glycogen Storage Disease Type IA; Interventions: DTX401, Placebo, Oral prednisolone; Enrollment: 52 (actual); First posted: 2021-12-01; Results posted: 2026-10-14; NCT: NCT05139316

02 THE STORY SO FAR

THE RECORD, IN ORDER.

STANDALONE ITEM — NOT YET FOLDED INTO A DEVELOPING STORY.

03 WHO'S INVOLVED

ENTITIES ON FILE.

AFFECTEDHealthcare

04 RECEIPTS

THE SOURCE RECORD.

1 SOURCES CONFIRMED
№ 01clinicaltrialsclinicaltrials.gov · PRIMARY2026-10-14 12:00 UTCOPEN RECEIPT →

05 PROPAGATION

WHAT THIS TOUCHES.

KEEP READING THE MACHINE

OPEN THE MACHINE →THE PREDICTION LEDGER →

Summaries are generated and may contain errors — every claim links its sources.